SOURCE: Holzer Holzer & Fistel, LLC

Holzer Holzer & Fistel, LLC

July 11, 2011 12:19 ET

Holzer Holzer & Fistel, LLC Announces That a Shareholder Class Action Has Been Filed on Behalf of Purchasers of BioMimetic Therapeutics, Inc. Securities

ATLANTA, GA--(Marketwire - Jul 11, 2011) - Holzer Holzer & Fistel, LLC announces that a class action lawsuit has been filed in the United States District Court for the Middle District of Tennessee on behalf all persons or entities who purchased BioMimetic Therapeutics, Inc. ("BioMimetic" or the "Company") (NASDAQ: BMTI) stock between October 14, 2009 and May 16, 2011 (the "Class Period"). The lawsuit alleges, among other things, that BioMimetic misrepresented the inadequacies of clinical trials for its experiential drug, Augment and, according to the lawsuit, the Company failed to disclose material adverse facts regarding Augment's safety and efficacy.

If you purchased shares of BMTI common stock during the Class Period, or have continuously held shares since at least October 14, 2009, and would like to discuss your legal rights, you may contact Michael I. Fistel, Jr., Esq., or Marshall P. Dees, Esq. via email at mfistel@holzerlaw.com, or mdees@holzerlaw.com, or via toll-free telephone at (888) 508-6832.

Holzer Holzer & Fistel, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.